Want to see SYBX full AI Analyst Report?
Top Page
Synlogic
(OTC:SYBX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.71
▼(-41.89% Downside)
Action:Reiterated
Date:07/30/26
The score is held down primarily by very weak fundamentals (minimal revenue, ongoing losses, and negative free cash flow), despite reduced burn and no reported debt. Technicals are mixed (short-term improvement but still below the 200-day trend), while valuation is hard to assess due to negative earnings. A major positive offset is the merger and accompanying financing, which improves funding visibility but appears to leave existing shareholders with a small stake in the combined entity.
Positive Factors
Merger with Caldera and $278M concurrent financing
A binding all-stock merger and a $278M institutional financing materially lengthen Synlogic’s cash runway and de-risk near-term financing. This structural funding supports planned Phase 2 development, enabling multi-year clinical programs and reducing execution risk tied to interim capital markets.
Negative Factors
Essentially no recurring revenue
The company remains pre-revenue and dependent on clinical progress and external capital to create commercial cash flow. Lack of recurring revenue makes long-term viability contingent on successful trials, regulatory approvals, and commercialization—structural risks for biotech developers.
Read all positive and negative factors
Positive Factors
Negative Factors
Merger with Caldera and $278M concurrent financing
A binding all-stock merger and a $278M institutional financing materially lengthen Synlogic’s cash runway and de-risk near-term financing. This structural funding supports planned Phase 2 development, enabling multi-year clinical programs and reducing execution risk tied to interim capital markets.
Read all positive factors
Synlogic (SYBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.04M
Dividend YieldN/A
Average Volume (3M)41.08K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue GrowthN/A
EPS Growth-138.25%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,696,641
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Synlogic Business Overview & Revenue Model
Company Description
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts....
How the Company Makes Money
null...
Synlogic Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 8.00K | 3.37M | 1.18M | 1.75M |
| Gross Profit | 0.00 | 0.00 | 8.00K | 3.37M | 1.18M | 1.75M |
| EBITDA | -3.57M | -3.53M | -22.06M | -55.31M | -63.63M | -58.12M |
| Net Income | -641.00K | -1.00M | -23.36M | -57.28M | -66.15M | -60.56M |
Balance Sheet | ||||||
| Total Assets | 14.61M | 15.45M | 19.83M | 75.55M | 110.86M | 174.74M |
| Cash, Cash Equivalents and Short-Term Investments | 14.11M | 14.67M | 18.86M | 47.75M | 77.63M | 128.59M |
| Total Debt | 0.00 | 0.00 | 0.00 | 17.27M | 20.30M | 20.59M |
| Total Liabilities | 2.06M | 3.58M | 7.08M | 32.90M | 28.25M | 27.47M |
| Stockholders Equity | 12.55M | 11.86M | 12.75M | 42.66M | 82.61M | 147.27M |
Cash Flow | ||||||
| Free Cash Flow | -3.32M | -4.36M | -31.67M | -51.83M | -57.62M | -52.88M |
| Operating Cash Flow | -3.32M | -4.36M | -31.66M | -51.61M | -56.89M | -52.20M |
| Investing Cash Flow | 155.00K | 167.00K | 25.34M | 38.77M | 58.35M | -53.25M |
| Financing Cash Flow | 0.00 | 0.00 | 172.00K | 20.94M | -2.04M | 89.38M |
Synlogic Technical Analysis
Positive
1.22
Price Trends
0.77
Positive
0.70
Positive
0.90
Positive
Market Momentum
0.13
Negative
82.19
Negative
82.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYBX, the sentiment is Positive. The current price of 1.22 is above the 20-day moving average (MA) of 0.87, above the 50-day MA of 0.77, and above the 200-day MA of 0.90, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 82.19 is Negative, neither overbought nor oversold. The STOCH value of 82.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYBX.
Synlogic Risk Analysis
Synlogic disclosed 34 risk factors in its most recent earnings report. Synlogic reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Synlogic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $12.51M | -0.76 | -146.29% | ― | 235.51% | 85.50% | |
47 Neutral | $14.04M | -22.68 | -5.42% | ― | ― | -138.25% | |
44 Neutral | $64.52M | -0.95 | -365.16% | ― | ― | 58.01% | |
43 Neutral | $5.12M | -0.01 | -198.50% | ― | ― | 99.36% | |
43 Neutral | $19.25M | -1.68 | -109.94% | ― | ― | 94.17% | |
41 Neutral | $9.02M | -0.53 | -101.90% | ― | -83.00% | 19.02% |
* Healthcare Sector Average
SYBX
Synlogic
1.20
-0.16
-11.76%
LSTA
Lisata Therapeutics
1.07
-1.73
-61.79%
APVO
Aptevo Therapeutics
4.07
-34.45
-89.43%
ICU
SeaStar Medical Holding
3.05
-4.85
-61.39%
CING
Cingulate Inc
5.05
0.84
19.95%
ALLR
Allarity Therapeutics
1.40
0.41
41.41%
Synlogic Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Synlogic to Merge into Newly Formed Caldera Therapeutics
Positive
Jul 29, 2026
On July 28, 2026, Synlogic and Caldera entered a definitive all-stock merger agreement that will see both companies become wholly owned subsidiaries of a new holding company, with the combined entity operating as Caldera Therapeutics and seeking a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.